Infliximab and adalimumab for the treatment of Crohn's disease

  • Technology appraisal guidance
  • TA187
  • Published: 
Download guidance (PDF)

Appendix B: Sources of evidence considered by the Committee

A. The assessment report for this appraisal was prepared by the West Midlands Health Technology Assessment Collaboration:

  • Dretzke J et al. Use of tumour necrosis factor alpha (TNF α) inhibitors (adalimumab and infliximab [review]) for Crohn's disease: a systematic review and economic evaluation, July 2008.

B. The Decision Support Unit (DSU) reports for this appraisal were prepared by The School of Health and Related Research, University of Sheffield:

  • Wailoo, A et al. Use of tumour necrosis factor alpha (TNF α) inhibitors (adalimumab and infliximab) for Crohn's disease: Report by the Decision Support Unit, January 2009.

  • Wailoo, A et al. Use of tumour necrosis factor alpha (TNF α) inhibitors (adalimumab and infliximab) for Crohn's disease: Report by the Decision Support Unit, June 2009.

C. The following organisations accepted the invitation to participate in this appraisal as consultees and commentators. They were invited to comment on the draft scope, assessment report and the appraisal consultation document (ACD). Organisations listed in I, II and III were also invited to make written submissions and have the opportunity to appeal against the final appraisal determination.

I) Manufacturers/sponsors:

  • Abbott Laboratories Ltd (adalimumab)

  • Schering Plough (infliximab)

II) Professional/specialist and patient/carer groups:

  • National Association for Colitis and Crohn's Disease (NACC)

  • Association of Coloproctology of Great Britain and Ireland

  • British Society of Gastroenterology

  • Royal College of Nursing

  • Royal College of Physicians

III) Other consultees:

  • Hammersmith and Fulham PCT

  • Department of Health

  • Welsh Assembly Government

IV) Commentator organisations (did not provide written evidence and without the right of appeal):

  • British National Formulary

  • Department of Health, Social Services and Public Safety for Northern Ireland

  • NHS Quality Improvement Scotland

  • Dr Falk Pharma UK Ltd (mesalazine, budesonide)

  • Ferring Pharmaceuticals Ltd (mesalazine) (Not participating)

  • Forest Laboratories UK Ltd (prednisolone) (Not participating)

  • Teva UK Ltd (mesalazine) (Not participating)

  • HalcyGen Pharmaceuticals Ltd (methotrexate) (Not participating)

  • Novartis Pharmaceuticals Ltd (ciclosporin)

  • Pfizer Ltd (sulfasalazine)

  • Procter and Gamble Pharmaceuticals (UK) Ltd (mesalazine)

  • Sandoz Ltd (mesalazine, metronidazole) (Not participating)

  • Sanofi-Aventis Ltd (sodium cromoglicate, metronidazole)

  • UCB Pharma Ltd (olsalazine sodium, prednisolone)

  • Winthrop Pharmaceuticals UK Ltd (metronidazole)

  • National Coordinating Centre for Health Technology Assessment

  • West Midlands Health Technology Assessment Collaboration

D. The following individuals were selected from clinical specialist and patient advocate nominations from the non-manufacturer/sponsor consultees and commentators. They participated in the Appraisal Committee discussions and provided evidence to inform the Appraisal Committee's deliberations. They gave their expert personal view on infliximab and adalimumab for the treatment of Crohn's disease by attending the initial Committee discussions and/or providing written evidence to the Committee. They were also invited to comment on the ACD.

  • Mr Charlie Croft, nominated by the National Association for Colitis and Crohn's Disease – patient expert

  • Ms Elaine Steven, nominated by the National Association for Colitis and Crohn's Disease – patient expert

  • Professor Subrata Ghosh, Consultant in General Medicine, Imperial College School of Medicine, nominated by the British Society of Gastroenterology – clinical specialist

  • Professor Sally Mitton, Consultant Paediatric Gastroenterologist, British Society for Paediatric Gastroenterology, Hepatology and Nutrition, nominated by the National Association for Colitis and Crohn's Disease – clinical specialist

  • Professor Chris Hawkey, President of BSG, nominated by British Society of Gastroenterology – clinical specialist (from August 2009)

  • Professor Jon Rhodes, Professor of Medicine and Honorary Consultant Gastroenterologist, nominated by the Royal College of Physicians – clinical specialist (from August 2009)

  • Dr Tim Orchard, Consultant Gastroenterologist, nominated by British Society of Gastroenterology – clinical specialist (from January 2010)

E. Representatives from the following manufacturers/sponsors attended Committee meetings. They contributed only when asked by the Committee chair to clarify specific issues and comment on factual accuracy.

  • Abbott Laboratories Ltd (adalimumab)

  • Schering Plough (infliximab)